Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.

Article Details

Citation

Wong D, van Duin D

Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.

Drugs. 2017 Apr;77(6):615-628. doi: 10.1007/s40265-017-0725-1.

PubMed ID
28303449 [ View in PubMed
]
Abstract

Carbapenem-resistant Enterobacteriaceae are amongst the most feared pathogens due to severely limited treatment options. In response to this threat, three novel beta-lactamase inhibitors have been developed in an attempt to reinvigorate and sustain our current antimicrobial therapies. Avibactam, vaborbactam, and relebactam are inhibitor agents with high affinity to Ambler class A and C beta-lactamases and favorable outcomes in current clinical trials. However, although they do possess key similarities, these agents have unique differences which may have important clinical implications. The microbiologic spectrum, pharmacokinetics, and key clinical trials for each of these novel agents are reviewed. A proposed role in therapy and potential novel combinations are examined.

DrugBank Data that Cites this Article

Drugs